Buprenorphine/Naloxone · larger labeled portfolio than Cyclobenzaprine
SPL labels Buprenorphine/Naloxone + Cyclobenzaprine as minor; Buprenorphine/Naloxone 19 / Cyclobenzaprine 14 in that band.
Mechanism on file: Both drugs can increase serotonin levels in your brain, which may cause a rare but serious reaction called serotonin syndrome.
FDA SPL severity: Minor
Buprenorphine/Naloxone + Cyclobenzaprine · SPL mechanism field
Both drugs can increase serotonin levels in your brain, which may cause a rare but serious reaction called serotonin syndrome.
Minor band excerpt · Buprenorphine/Naloxone with Cyclobenzaprine
Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy...
Buprenorphine/Naloxone · 19 SPL pairs (broader portfolio than Cyclobenzaprine)
- Buprenorphine minor
- Carbamazepine minor
- Darunavir minor
- Erythromycin minor
Cyclobenzaprine · 14 minor + 17 total pairs
- Acetaminophen/Oxycodone minor
- Buprenorphine minor
- Buprenorphine (Pain) minor
- Codeine minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.